Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 04/09/12 -- Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere.
In an exclusive interview, Timothy Mayleben, who has served as Aastrom's President and CEO since late 2009, explains how the financing came to be and why investors sought out his firm to place the big bet on their future.
Aastrom Biosciences is a regenerative medicine company engaged in the development of autologous cell products for treatment of severe, chronic cardiovascular diseases. Their proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The cellular therapy resulting from this process contains expanded populations of mixed stem and progenitor cells to support the regeneration of cardiovascular tissue. The company's cell manufacturing process works exclusively with adult stem cells derived from and administered to the same patient. This approach reduces the risk of rejection and increases the likelihood of integration with the surrounding tissues, eliminating the need for immunosuppressive drugs.
Mayleben's exclusive interview with BioMedReports is now available at:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
News developments and live healthcare sector updates are available constantly via Twitter at:
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com
Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2012 - 08:45 Uhr
Sprache: Deutsch
News-ID 1100973
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LOS ANGELES, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
